Multi-omics integration and in vitro validation identify IL4R, IMPA2, and PRR4 as key therapeutic targets in chronic rhinosinusitis with nasal polyps - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Integration of Multi-Omics Data and In Vitro Analysis Reveals IL4R, IMPA2, and PRR4 as Significant Therapeutic Targets in Chronic Rhinosinusitis with Nasal Polyps

  • By

  • Bo Wei

  • Weigang Gan

  • Jiaxin Li

  • Feng Wang

  • Jun Wang

  • Binbin Wang

  • Jiaoyu He

  • Feng Liu

  • June 15, 2026

Share

  • 1

    This study identifies IL4R, IMPA2, and PRR4 as significant therapeutic targets in chronic rhinosinusitis with nasal polyps (CRSwNP).

  • 2

    Multi-omics data integration revealed 4460 differentially expressed genes and 732 hub genes related to CRSwNP pathogenesis.

  • 3

    Machine learning analysis highlighted IL4R and IMPA2 as upregulated and PRR4 as downregulated in CRSwNP, indicating their roles in the disease.

  • 4

    In vitro experiments demonstrated that targeting IL4R and IMPA2, and overexpressing PRR4, can protect against inflammation and restore epithelial integrity.

  • 5

    The findings provide new molecular targets and potential therapeutic drugs for improving diagnosis and treatment strategies for CRSwNP.

Original Source(s)

Related Content